The U.S. Food and Drug Administration (FDA) has approved a medication called dapagliflozin for adults with type 2 diabetes. This drug, taken as a tablet, works in two ways. First, it is approved to help improve blood sugar control when used along with diet and exercise. Second, and importantly, it is approved to reduce the risk of hospitalization for heart failure in patients who already have heart disease or have multiple risk factors for it.
This approval means doctors now have another option for treating type 2 diabetes that also addresses a major heart-related risk. For the right patients, it can be a single medication that helps manage both blood sugar and heart health. The FDA's decision is based on clinical studies showing these benefits in a specific group of people.
It is important to know this medication is not for everyone. It is not recommended for people with type 1 diabetes. It is also not recommended for managing blood sugar in people with type 2 diabetes who have significantly reduced kidney function. The prescribing information includes specific guidance on this.
As with any new treatment option, this approval is a medical development for doctors to consider. Patients should talk with their own doctor to understand if this medication might be a suitable part of their personal care plan, based on their full health history and current condition.